Category: Foundation Medicine

Foundation Medicine, Epic partner to integrate genomic insights into EHR

BioPharma, biopharma nl, Daily, EHRs, Epic, Foundation Medicine, Genomic Testing, Health IT, News, orders, Partnership, results, SYN, Top Story / August 26, 2021 August 26, 2021

As a result of the partnership, clinicians using Epic will be able to order Foundation Medicine’s genomic profiling tests directly from the EHR and view results in the system, providing them with clinical decision support.

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care

cancer, Cancer Detection, Cancer Genomics, EMR, EMR/EHR, Epic EHR Integration, epic emr, Foundation Medicine, Genomics-Based Clinical Decision Support Tools, Health IT, Precision Medicine, Precision Medicine Oncology / August 26, 2021 August 26, 2021

What You Should Know: – Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop …

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care Read More »

Foundation Medicine Integrates Genomic Profiling with Flatiron Health’s EMR

EHR integration, EMR, EMR/EHR, Flatiron Health, Foundation Medicine, Health IT / June 29, 2021 June 29, 2021

What You Should Know: – Foundation Medicine (FMI) announced today it will begin integrating with Flatiron Health and other electronic medical record (EMR) systems to make it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to quickly and efficiently develop personalized treatment …

Foundation Medicine Integrates Genomic Profiling with Flatiron Health’s EMR Read More »

Getting the right data to doctors is next hurdle for precision medicine

2bPrecise, BioPharma, biopharma nl, Color, Daily, Diagnostics, Foundation Medicine, genetic testing, News, Personalized Medicine, Physicians, precision med virtual 2020, Precision Medicine, Strata Oncology, SYN, Top Story / December 11, 2020 December 11, 2020

The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.

String of FDA approvals gives momentum to liquid biopsies

BioPharma, California, companion diagnostics, Daily, Diagnostics, FDA approval, Foundation Medicine, grail, Guardant Health, Illumina, Liquid Biopsy, Massachussets, News, Penn State Hershey Medical Center, SYN, Top Story / November 4, 2020 November 4, 2020

Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.

Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib)

Across, All, approval, Companion, Diagnostic, Foundation Medicine, FoundationOne CDx, Fusions, Identify, larotrectinib, MedTech, NTRK, patients, receives, regulatory, Solid, tumors, U.S.FDA, Vitrakvi / October 26, 2020 October 26, 2020

Shots: The US FDA approved FoundationOneCDx to be used as a CDx for Vitrakvi (larotrectinib) to identify patients with NTRK fusions across all solid tumors. The genomic test is currently approved as a CDx for 20+ therapies The FoundationOne CDx is the tissue-based CGP test approved to detect NTRK1/2/3 fusions across all solid tumor types …

Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib) Read More »

Foundation Medicine to launch liquid biopsy companion diagnostic following FDA approval

biopharma nl, Cambridge, Daily, Diagnostics, Foundation Medicine, FoundationOne Liquid CDx, Liquid Biopsy, Massachusetts, Precision Medicine, SYN, Top Story / August 28, 2020 August 28, 2020

The company announced Wednesday the FDA approval of its liquid biopsy test, the second to win an agency nod in less than a month, saying it would launch the product on Friday. The FDA acquired the first ever liquid biopsy companion diagnostic, Guardant Health’s Guardant360 CDx, on Aug. 10.